DELAWARE, Ohio, Feb. 26, 2025 (GLOBE NEWSWIRE) — Greif, Inc. (NYSE: GEF, GEF.B), a global leader in industrial packaging products and services, today announced fiscal first quarter 2025 results. Fiscal First Quarter 2025 Financial Highlights: (all results compared to the first quarter of 2024 unless otherwise noted)Net income decreased 87.2% to $8.6 million or $0.15 per diluted Class A share compared to net income of $67.2 million or $1.17 per diluted Class A share, primarily due to a non-recurring income tax benefit of $48.1 million in the prior year quarter. Net income, excluding the impact of adjustments(1), decreased 69.1% to $22.5 million or $0.39 per diluted Class A share compared to net income, excluding the impact of adjustments, of $72.7 million or $1.27 per diluted Class A share. Adjusted EBITDA(2) increased 5.9% to...

Record full year subscription revenue of $99.6 million, up 14% year-over-year Q4 annualized recurring revenue (ARR) grows to $104.2 million Record full year total revenue of $169.7 million Total subscribers grew to 1.2 million, up 23% year-over-yearSUNNYVALE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) — Matterport, Inc. (Nasdaq: MTTR) (“Matterport” or the “Company”), the leading spatial data company driving the digital transformation of the built world, today announced financial results for the quarter and year ended December 31, 2024. “I’m pleased to share our fourth quarter and full year 2024 results, highlighting our continued success driving efficient growth while doubling down on innovation. Total square feet digitized and managed reached a significant company milestone of 50.7 billion, up 33% year-over-year, with annual recurring...

PURCHASE, NY, Feb. 26, 2025 (GLOBE NEWSWIRE) — Teladoc Health, Inc. (NYSE: TDOC), the global leader in whole-person virtual care, today reported financial results for the full year ended December 31, 2024 (“Full Year 2024”) and three months ended December 31, 2024 (“Fourth Quarter 2024”). Unless otherwise noted, percentage and other changes are relative to the full year ended December 31, 2023 (“Full Year 2023”) and three months ended December 31, 2023 (“Fourth Quarter 2023”). Full Year and Fourth Quarter 2024 HighlightsFull Year 2024 revenue of $2,569.6 million, down 1% year-over-year, and Fourth Quarter 2024 revenue of $640.5 million, down 3% year-over-year Full Year 2024 net loss of $1,001.2 million, or $5.87 per share, and Fourth Quarter 2024 net loss of $48.4 million, or $0.28 per share Full Year 2024 adjusted EBITDA of...

Good profitability and cash flow generationdespite slower growth in 2024 2024 key figuresRevenue: €2,441 million (+2.1% compared to 2023)organic growth: +1.3% external growth: +2.3%Operating margin rate: 13.1% Free cash flow generation: €216 millionBen Page, CEO of Ipsos, stated: “Despite slowing growth, the improvement in gross margin and careful cost management enabled us to deliver a good level of profitability. Ipsos’ financial health is also reflected in strong cash generation, virtually debt-free status and Investment Grade ratings by Moody’s and Fitch. Our recent acquisitions have cemented our leadership in Public Affairs and Data Analytics. Finally, we will continue to invest in our panels, platforms and Generative AI to deliver even faster cutting-edge insights to our clients.” Paris, 26 February 2025 – Ipsos, one of...

       2024 Full-Year Results: a very active year, a dual model in place, strong value creation & a growing return to shareholders Fully diluted1 Net Asset Value per share of €185.7, representing a +16.9% year-over-year value creation, adjusted for the dividend paid Dividend boosted at €4.7 per share, up +17.5% year-over-year Strong portfolio rotation: more than €2 billion of capital reallocation Significant expansion of the Asset Management platform in Europe and US, and development of our dual business model towards more recurring cash flows and growth Fully diluted Net Asset Value2 as of December 31, 2024: €185.7 per share, up +14.4%Value creation of +16.9%3 over 2024, adjusted for the €4 dividend paid in May 2024 reflecting:The increase in Bureau Veritas’ share price (+28.3% YoY) on the back of the quality of its LEAP |...

Banco Comercial Português, S.A. informs about consolidated earnings in 2024 AttachmentsEarnings Millennium BCP FY24_finalEarningsPres 12M24

Ivry-sur-Seine, February 26, 2025, 5:45 p.m. CET STRONG 2024 ANNUAL RESULTS, TARGETS EXCEEDED1 RELEVANCE OF THE TRANSFORMATION DRIVEN BY THE STRATEGIC PLAN EVERYDAYEUROPEAN LEADERSHIP STRENGTHENED WITH THE ACQUISITION OF UNIEURO SALES GROWTH AND MARKET OUTPERFORMANCE1Revenue: +1% to nearly €8bn Growth in omnichannel sales: +1.7 points, 52% of the Group’s online sales  Increased market share at major end-of-year commercial eventsGROWTH IN GROSS MARGIN AND 2024 CURRENT OPERATING INCOME TARGET ACHIEVED1Gross margin at 30.6% (vs. 30.2% in 2023), driven by Services, which contributed +50 bps Current operating income: €182m (+6% vs. 2023): proof of the effectiveness of the performance plans implemented in all departments2021–2024 CUMULATIVE FREE CASH-FLOW FROM OPERATIONS: TARGET EXCEEDED1€195m generated in 2024, an increase of...

        PRESS RELEASE                Paris, 26th February 2025 Half-year results at the end of December 2024 Confirmed fundamentalsStrengthening access to healthcare for all as a mission-driven company, Ramsay Santé, thanks to its employees and medical community, expands its pioneering role in access to care and medical innovation benefiting 12.6 million patients in France, Nordics and Italy. 95% of French Ramsay Santé facilities certified to the highest standards of quality of care by the Haute Autorité de Santé (French National Authority for Health) vs. 86% nationally. NPS reaching an all-time high with 73% of patients recommending Ramsay Santé in France.Activity growth, cost control to mitigate pricing headwindsGroup revenue increased by 5.8% to €2.5bn supported by activity volume growth and Cosem primary care centres acquired...

   Paris, February 26, 2025 RAMSAY SANTE Half-year Financial Report as at end of December 2024 disposal   This document is available on RAMSAY SANTE Internet site : http://www.ramsaysante.fr About Ramsay Santé : Ramsay Santé is leader in private hospitalisation and primary care in Europe. The Group has 38,000 employees and works with nearly 9,300 practitioners to treat more than 12 million patients per year in its 465 facilities and 5 countries: France, Sweden, Norway, Denmark and Italy. Ramsay Santé offers almost all medical and surgical specialities in three domains: Medicine, Surgery, Obstetrics (MSO), Follow-up Care and Rehabilitation (FCR) and Mental Health.Legally, Ramsay Santé is a mission-driven company committed to constantly improving the health of all patients through innovation. Wherever it operates, the Group...

On track to announce the primary endpoint result from the atacicept pivotal Phase 3 ORIGIN trial in IgA Nephropathy (IgAN) in 2Q 2025; BLA submission to the U.S. FDA for accelerated approval planned in 2H 2025 Expanded atacicept clinical development program in multiple autoimmune kidney diseases proceeding in 2025 Strengthened balance sheet to support clinical pipeline development, planned FDA submission, and potential 2026 commercial launch of atacicept for the treatment of IgANBRISBANE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the fourth quarter and full year ended...